ZHONGZHIPHARM (03737) · Company profile · Eqvero

ZHONGZHIPHARM

03737HKEX

Unit: CNY	FY2025	FY2024	FY2023	FY2022	FY2021
Revenue	1.74 bn CNY	2.21 bn CNY	2.05 bn CNY	1.83 bn CNY	1.75 bn CNY
Cost of revenue	694.75 m CNY	822.02 m CNY	733.13 m CNY	662.2 m CNY	600.1 m CNY
Research and development expense	41.46 m CNY	57.01 m CNY	49.98 m CNY	46.35 m CNY	43.83 m CNY
Selling, general and administrative expense	893.86 m CNY	1.09 bn CNY	994.81 m CNY	914.57 m CNY	932.14 m CNY
Operating profit after depreciation	-1.67 m CNY	125.14 m CNY	163.93 m CNY	103.51 m CNY	79.58 m CNY
Operating profit before depreciation	100.81 m CNY	236.56 m CNY	266.01 m CNY	199.89 m CNY	164.63 m CNY
EBIT	-1.67 m CNY	125.14 m CNY	163.93 m CNY	103.51 m CNY	79.58 m CNY
EBITDA	100.81 m CNY	236.56 m CNY	266.01 m CNY	199.89 m CNY	164.63 m CNY
Interest expense	5.38 m CNY	6.99 m CNY	7.87 m CNY	6.56 m CNY	7.08 m CNY
Profit before tax	18.99 m CNY	146.9 m CNY	207.58 m CNY	130.65 m CNY	61.81 m CNY
Income tax expense	1.29 m CNY	50.75 m CNY	43.45 m CNY	23.74 m CNY	9.45 m CNY
Income before extraordinary items	17.29 m CNY	95.21 m CNY	162.78 m CNY	106.39 m CNY	52.13 m CNY
Common dividends	—	39.85 m CNY	71.05 m CNY	45.34 m CNY	—
Total dividends	—	39.85 m CNY	71.05 m CNY	45.34 m CNY	—

Quotes are end-of-day data. Content is for research purposes and is not investment advice.